Full-Time
Vice President – Medtech & Devices
Hippocratic AI
201-500 employees
Licenses safety-focused healthcare LLMs to institutions
No salary listed
Palo Alto, CA, USA
In Person
Palo Alto office five days on-site required.
 Sales & Account Management (1) |
|---|
- 7–15 years of experience in medical device commercial operations, patient engagement, clinical support, field operations, or related functions within device manufacturers, medtech services organizations, or healthcare services companies serving the device industry.
- Deep, hands-on operational knowledge of medical device workflows including surgical case support, post-surgical patient follow-up, device onboarding and training, field clinical operations, complaint handling, post-market surveillance, device registries, and HCP engagement programs.
- Direct experience building, managing, or designing device patient support programs, clinical education initiatives, or field operations — not just selling into them or advising from the outside.
- Demonstrated ability to engage credibly with senior medtech executives (VP, SVP, C-suite) across commercial, clinical, service, quality, and regulatory functions — and to drive deals to close, not just build relationships.
- Experience translating operational knowledge into solution design, product requirements, go-to-market strategy, or technology platform capabilities.
- Strong understanding of the medical device commercial model — capital equipment vs. consumables vs. implantables dynamics, surgeon preference and adoption cycles, hospital and ASC procurement, GPO contracting, and field sales and clinical specialist operating models.
- Comfort with commercial ownership — pipeline targets, revenue accountability, and the expectation that you are building a business line, not just advising on one.
- Comfort working in high-growth environments with limited structure and high expectations for ownership, cross-functional collaboration, and hands-on contribution across strategy, selling, and delivery.
- Exceptional communication skills — written, verbal, and visual — with the ability to make complex device operations accessible to technical, commercial, and executive audiences.
- Own the medtech vertical end-to-end — from market positioning and pipeline generation through solution design, enterprise sales, deployment, and account expansion; you are the single-threaded leader responsible for how Hippocratic AI wins in medical devices.
- Define and execute the AI-powered solution roadmap across the full device lifecycle: pre-surgical education, surgical scheduling, post-op recovery, implant tracking, patient onboarding, HCP training, field support, complaint handling, clinical evidence generation, and post-market surveillance; translate this roadmap into revenue.
- Develop systems-level solution architectures that reflect how AI agents interact with surgeons, clinical staff, field teams, quality and regulatory leaders in high-pressure, real-world clinical and commercial environments.
- Prioritize ruthlessly based on the intersection of market demand, revenue potential, and deployment feasibility — ensuring the highest-impact solutions move first and the team isn't spread thin on low-signal opportunities.
- Serve as the primary external face of Hippocratic AI in medtech; you are the credible authority in enterprise sales conversations, C-suite workshops, industry conferences, and strategic partnerships; not a support function behind a seller, but the person in the room closing.
- Own the medtech go-to-market motion: positioning, messaging, target account strategy, pipeline development, and deal progression. Partner with marketing to build category-defining content, event strategy, and demand generation programs that reflect deep domain credibility.
- Drive enterprise deal velocity by partnering directly with device company executives across commercial, quality, regulatory, and clinical functions to validate use cases, structure pilots, and build the trust required to move from evaluation to full-scale platform adoption.
- Build and own the economic narrative. Translate AI capabilities into hard-hitting ROI frameworks and financial models — reduced call center load, improved patient compliance, accelerated surgeon onboarding, lower complication-related costs — that resonate with CFOs and operating committees, not just innovation teams.
- Translate surgical workflows, field operations realities, and regulatory constraints into precise requirements, conversation designs, and acceptance criteria for Engineering and Product.
- Collaborate with Medical Affairs and Quality to ensure every AI solution meets stringent FDA post-market requirements, MDR/IVDR obligations, and promotion-compliance standards. You don't hand this off — you understand it well enough to make real-time judgment calls.
- Partner with Customer Success to define the deployment standard for medtech — creating readiness playbooks, implementation checklists, and go-live protocols that ensure zero-friction launches in live clinical settings. Own customer outcomes post-deployment, not just pre-sale enthusiasm.
- Build and maintain the internal source of truth for medtech — covering surgical adoption cycles, hospital and ASC procurement dynamics, GPO contracting, value-based models, and competitive landscape.
- Raise the medtech IQ of the entire organization. Develop training materials and internal enablement programs that allow cross-functional teams to engage credibly with surgeons, device manufacturers, and health system procurement leaders.
- Proactively identify ecosystem shifts — Hospital-at-Home, ASC growth, remote patient monitoring, connected devices, evolving reimbursement models — and position the platform to capture emerging opportunities before they become consensus.
- As the vertical matures, scope includes building and leading a dedicated medtech team across solutions, sales support, and customer delivery.
- Experience at a major medical device manufacturer or medtech services organization in an operational, commercial, strategy, or product capacity.
- Familiarity with device industry technology platforms including CRM systems, field service management tools, surgical scheduling systems, device telemetry platforms, and EHR integration standards.
- Understanding of FDA device regulations, 510(k) and PMA pathways, post-market surveillance requirements, MDR/IVDR, UDI, and quality system regulations as they relate to commercial operations and patient engagement.
- Experience leading or heavily influencing enterprise sales or go-to-market efforts as a subject matter expert, solutions lead, or commercial owner.
- Understanding of reimbursement dynamics including DRG, ASP, bundled payments, and value-based device contracting as they intersect with device adoption and patient support.
- Experience with AI, digital health, remote monitoring, or connected device technologies.
- Startup or early-stage company experience with direct revenue or P&L-adjacent accountability.
- Advanced degree (MBA, MS, MSE, PhD) or clinical degree (MD, RN, PA) is a plus.
Hippocratic AI develops specialized language models for healthcare, licensing them to hospitals and clinics to improve patient care and operational efficiency. The models are trained on evidence-based medical content and refined with a Reinforcement Learning with Human Feedback process involving healthcare professionals to ensure safety and accuracy. Unlike general-purpose LLMs, its focus on safety, equity, bedside manner, and real-world deployment differentiates it from competitors. The goal is to improve healthcare access, equity, and outcomes by providing safe, reliable AI tools for providers and patients.
Company Size
201-500
Company Stage
Series C
Total Funding
$402M
Headquarters
Palo Alto, California
Founded
2022
Simplify's Take
What believers are saying
- Nurse Co-Pilot returns one to four hours per nurse each shift.
- UNC Health and Cincinnati Children's validate enterprise demand across complex care settings.
- BCG collaboration and five-pharma deployments can accelerate life-sciences expansion.
What critics are saying
- Any severe harm event undermines Hippocratic AI's safety-first brand immediately.
- Epic and Oracle Health can absorb low-risk workflows inside existing EHRs.
- Large-model voice economics compress margins if competitors match performance cheaper.
What makes Hippocratic AI unique
- Polaris 5.0 targets non-diagnostic healthcare conversations with licensed-clinician validation.
- AI Front Door unifies scheduling, billing, lab results, and care instructions.
- Grove AI acquisition adds participant relationship management for life-sciences workflows.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Hippocratic AI who can refer or advise you
Benefits
Remote Work Options
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↓ -1%2 year growth
↑ 0%Hippocratic AI launches two industry firsts: AI Front Door and Nurse Co-Pilot to expand clinical care and access. PR Newswire Today at 11:30am PDT PR Newswire PALO ALTO, Calif., Apr. 16, 2026 The first safe, omni-topic Voice AI for patient access, including inbound calls and the first AI voice assistant built for inpatient nurses - giving healthcare leaders the tools to move from scarcity to abundance PALO ALTO, Calif., Apr. 16, 2026 /PRNewswire/ - Hippocratic AI today announced two new Voice AI products that mark a turning point in how healthcare organizations deliver care: AI Front Door, a safe, always-available AI health agent that replaces fragmented call centers and digital front doors with a single, continuous patient relationship over multiple calls, delivering omni-topic care across all patient needs; and Nurse Co-Pilot, the first AI voice assistant built specifically for inpatient nurses, co-developed with Cincinnati Children's Hospital Medical Center, OhioHealth, and Cleveland Clinic, designed to return 1-4 hours of nursing per shift. Both products are powered by Hippocratic AI's patented Polaris safety architecture - with 180+ million patient interactions, 99.90% correct clinical advice, 0.00% severe harm events, and validation from 7,500+ U.S.-licensed clinicians. "For all of healthcare's history, care has been designed around the assumption of scarcity," said Munjal Shah, CEO and co-founder of Hippocratic AI. "AI Front Door and Nurse Co-Pilot change that equation. One gives every patient a personal health agent. The other gives every nurse an AI assistant. Together, they put healthcare leaders in control of a shift from scarcity to abundance." AI FRONT DOOR: ONE AGENT. EVERY NEED. EVERY CHANNEL. The "digital front door" promised access but delivered phone trees, long hold times, and disconnected experiences. AI Front Door replaces this with a single intelligent agent that resolves needs in one continuous conversation instead of deflecting them. Omni-topic. A patient can schedule an appointment, ask about lab results, address a billing issue, and follow up on care instructions, all in one conversation, no transfers, no restarts. Relationship-based. Every interaction builds on the last. The AI remembers patient history, preferences, and prior conversations, shifting the experience from transactional to longitudinal. Less call center, more care. Patient advocate. AI Front Door prepares patients before visits, follows up afterward, and closes care gaps in between - serving as a continuous member advocate, guiding members through benefits, preparing them for appointments, and keeping care plans on track. Operates externally - It doesn't stop at answering questions. The AI coordinates referrals, arranges transportation, contacts employers, and manages the logistics that typically fall through the cracks. Omnichannel. Start on the phone, continue over text, finish in the app - one seamless conversation that never loses context. Caregiver in the loop. Whether a patient has a caregiver or is one, AI Front Door keeps everyone connected - authorizations, status updates, and care discussions, all coordinated. "Every time a patient calls, that's a window of engagement, even if the initial call is just to reset a password. Most systems squander it - transfers, hold times, callbacks. AI Front Door doesn't. It resolves the need right there, powered by 31 coordinated LLM models that can safely navigate any topic, from scheduling to clinical needs in a single conversation." - Vishal Parikh, Chief Product Officer, Hippocratic AI. AI Front Door is already being deployed with initial partners, including Wellspan and Cincinnati Children's with more healthcare leaders coming on board this month. NURSE CO-PILOT: THE FIRST AI BUILT FOR BEDSIDE NURSES, BY NURSES While most healthcare AI has focused on physician documentation and administrative workflows, nurses, the largest segment of the clinical workforce, have seen little of that investment. Nurse Co-Pilot is designed to take work away from nurses, not pile more on. Co-developed with nursing leaders at Cincinnati Children's, OhioHealth, and Cleveland Clinic, it launches with four critical inpatient workflows: Admission Education - Walks newly admitted patients through what to expect, giving nurses time back for hands-on care. Patient Education - Delivers consistent education throughout the stay, from disease management to discharge preparation. Caregiver Engagement - Prepares family members for life after discharge: medications, warning signs, follow-ups, daily routines. The education that prevents readmissions. Medication Adherence - Walks patients through every medication so they leave informed and adherent. Each workflow, if executed by a nurse, will take from 10-15 minutes. By deploying Nurse Co-Pilot, the result can be 1-4 hours returned per nurse, per shift, depending on usage back to direct patient care. How it works: A nurse launches Nurse Co-Pilot directly from the EHR, selects the patient and workflow, and the AI calls the patient by phone - no app download required. After the call, a structured clinical summary and full transcript are written back to the EHR automatically. The nurse triggers every call, reviews every result, and maintains full clinical oversight. The AI is the tool; the nurse is the clinician. "There's never been enough time in a shift to reach every patient the way you want to," said Amy McCarthy, Chief Nursing Officer, Hippocratic AI. "Nurse Co-Pilot gives nurses an AI assistant that ensures every patient gets the follow-up they need, while giving nurses time back for hands-on care." ABOUT HIPPOCRATIC AI Hippocratic AI is building the safety layer for healthcare AI. The company's patented Polaris safety architecture ensures that AI agents in healthcare meet the highest standards of clinical safety, validated by licensed healthcare professionals. Founded by Munjal Shah, the company is headquartered in Palo Alto, California. For more information, visit hippocraticai.com. SOURCE Hippocratic AI This is a paid placement. For further inquiries, please contact PR Newswire directly.
Hippocratic AI consolidates Life Sciences leadership with acquisition of Grove AI and key executive appointments. The move establishes a dedicated Life Sciences Division and senior executive advisory council to accelerate generative AI across the biopharma and medtech value chain. PALO ALTO, Calif. - (BUSINESS WIRE) - #GenAI - Hippocratic AI, the global leader and pioneer in patient-facing generative AI healthcare agents, today announced a major expansion of its life sciences business. The company has acquired Grove AI, appointed a President of Life Sciences, launched a world-class Life Sciences Executive Advisory Council, and entered into a strategic collaboration with Boston Consulting Group (BCG). Together, these milestones establish Hippocratic AI as the category leader in deploying safe, scalable, and clinically grounded generative AI across the biopharma and medtech value chain, from R&D and clinical trials to commercialization and post-market patient engagement. "Real impact in the life sciences sector requires deeply specialized models, exhaustive safety testing, and LLM safety architectures built to operate within highly regulated environments," said Munjal Shah, Co-founder and CEO of Hippocratic AI. "That is why Hippocratic AI has strategically expanded its life sciences leadership - acquiring Grove AI, appointing a dedicated President of Life Sciences, convening a world-class Executive Advisory Council, and partnering with Boston Consulting Group." Hippocratic AI's generative AI agents are powered by its proprietary Polaris safety architecture, delivering high-fidelity clinical reasoning and enterprise-grade auditability at scale. Backed by more than 150 million clinical interactions to date and following its recent $126M Series C financing, with a portion of proceeds earmarked for M&A, the company is continuing to scale production-ready generative AI agents that life sciences organizations can trust across research, clinical, and patient engagement workflows. Acquisition of Grove AI to Accelerate Clinical Engagement Capabilities Hippocratic AI has acquired Grove AI, a leader in agentic AI for pharma R&D and clinical trial operations, uniting two teams aligned around a shared vision of healthcare abundance, expanding access, accelerating research, and removing friction across the life sciences ecosystem. Grove AI's team and technology now form a core pillar of Hippocratic AI's Life Sciences Division. Over the past year, Grove AI's platform supported more than 10 million patient interactions, uncovering opportunities to automate and transform thousands of slow, manual workflows across clinical research and development. "At Grove AI, we built the leading agentic AI solution for pharma R&D by working directly with clinical teams and patients at scale," said Tran Le, Co-Founder of Grove AI. "By joining Hippocratic AI, we can build on that foundation and accelerate the delivery of these capabilities to a much broader set of life sciences organizations, combining our innovation with Hippocratic AI's enterprise scale." The acquisition brings two cornerstone offerings to Hippocratic AI's life sciences portfolio: * AI Agent ("Grace"): an always-on, multilingual AI agent that supports end-to-end patient engagement, recruitment, and follow-up across voice, text, and email. * Grove AI PRM(TM)(Participant Relationship Management): a purpose-built platform that orchestrates AI-driven participant interactions with full transparency, human oversight, and regulatory alignment. "With our combined expertise, Hippocratic AI and Grove AI are uniquely positioned to lead the agentic AI transformation at a critical inflection point for the life sciences industry," said Sohit Gatiganti, Co-Founder of Grove AI. Today, the combined team is actively collaborating with five of the world's leading global pharmaceutical companies to deploy AI agents for patient and provider engagement at enterprise scale. Launch of Life Sciences Executive Advisory Panel To guide product development and ensure real-world relevance, Hippocratic AI has convened a Life Sciences Executive Advisory Panel, featuring seasoned leaders from the world's most respected pharmaceutical and medical device companies: * Jim Meyers, former Chief Commercial Officer at Gilead Sciences, who led the launch of 24 products, including 11 blockbuster brands. * Michael Norton, former VP of Global Medical Affairs at AbbVie, with over 20 years in R&D and medical leadership across AbbVie and Abbott. * David Pierce, former President of MedSurg, Endoscopy, and Urology at Boston Scientific, where he helped grow the company to over $20B in revenue. * Richard Klausner, former Director of the National Cancer Institute, former Executive Director at the Gates Foundation, and Co-founder of Altos Labs, a leading biotechnology company with more than $3 billion in funding, as well as Lyell Immunopharma, Juno Therapeutics, and Grail. This executive advisory panel brings deep expertise across therapeutic areas, commercialization, medical affairs, quality, and device innovation, ensuring Hippocratic AI's offerings are tuned to the evolving needs of life sciences partners. "I decided to join Hippocratic AI as an advisor due to the team's commitment to innovation that puts the patient and patient safety first. Their proven track record of supporting millions of patient clinical calls, powered by the Polaris Constellation Architecture, uniquely positions them to continue to drive meaningful change across life sciences. I am excited to apply my extensive industry experience during this pivotal period to help deepen the company's vertical expertise and navigate this complex landscape," said Jim Meyers, former Chief Commercial Officer at Gilead Sciences. Newly Appointed President of Life Sciences Leading the Life Sciences Division is Dr. Ahad Wahid, M.D., President of Life Sciences at Hippocratic AI. A former NHS surgeon and member of the UK General Medical Council's Quality Assurance Board, Dr. Wahid brings deep expertise in patient safety and regulatory rigor. He later spent a decade as a Partner at Boston Consulting Group, where he led global AI and healthcare transformation initiatives and advised executive teams and boards at more than 30 of the world's leading healthcare organizations. At Hippocratic AI, Dr. Wahid applies this combined clinical and strategic perspective to ensure AI adoption enhances care delivery while meeting the highest safety standards. "Hippocratic AI is building what life sciences has been waiting for: generative AI that can scale globally without compromising safety or regulatory integrity. The acquisition of Grove AI, combined with our expanded leadership team, advisory council, and collaboration with BCG, gives us the foundation to further operationalize agentic AI across research, clinical, and patient engagement workflows. My focus is ensuring these technologies are deployed responsibly, measurably, and at enterprise scale so innovation translates into real outcomes for patients and organizations alike," said Dr. Ahad Wahid, M.D., President of Life Sciences at Hippocratic AI. Strategic Collaboration with Boston Consulting Group As previously announced last week, Hippocratic AI has entered into a strategic collaboration with Boston Consulting Group (BCG) and BCG X to help pharma and medtech clients adopt generative AI solutions aligned with commercial, R&D, and medical affairs goals. Life sciences requires a strategic roadmap and deep understanding of regulatory requirements. BCG and Hippocratic AI will collaborate to bring integrated AI strategies, implementation services, and measurable ROI to the life sciences sector. This collaboration builds on BCG's AI transformation leadership and Hippocratic AI's pioneering generative AI healthcare agents, which are designed for safety, patient trust, and scale. "This collaboration is about closing the value gap in the industry by bringing together Hippocratic AI's sophisticated AI agent platform, BCG's strategy and governance expertise, and BCG X's Health Care Commercial AI solution to help clients turn potential into measurable business value," said Ashkan Afhkami, BCG managing director and senior partner and global leader for the Health Care practice at BCG X. About Hippocratic AI Hippocratic AI has developed the safest generative AI Agents for healthcare. The company believes that generative AI has the ability to bring healthcare abundance to every person in the world. The company focuses on building non-diagnostic patient-facing clinical AI agents and does not allow its agents to be used to prescribe or diagnose. Hippocratic AI has received a total of $404 million in funding and is backed by leading investors, including Andreessen Horowitz, General Catalyst, Kleiner Perkins, Avenir, NVIDIA's NVentures, Premji Invest, SV Angel, Google's CapitalG, and numerous health systems. Learn more at https://hippocraticai.com/.
Hippocratic AI, a leader in patient-facing generative AI healthcare agents, has acquired Grove AI and announced key strategic moves to expand its life sciences business. The company has appointed Dr Ahad Wahid as President of Life Sciences, launched a Life Sciences Executive Advisory Council, and entered a strategic collaboration with Boston Consulting Group. Grove AI's platform, which supported over 10 million patient interactions in the past year, will form a core pillar of Hippocratic AI's Life Sciences Division. The acquisition brings AI-driven patient engagement tools for clinical trials and R&D workflows. The advisory panel includes former executives from Gilead Sciences, AbbVie and Boston Scientific. Hippocratic AI has raised $404 million to date and currently supports 150 million clinical interactions, working with five major global pharmaceutical companies.
Anthropic, Genmab partner to use Claude for R&D and more digital health news. Hippocratic AI partners with Boston Consulting Group, and Verana Health merges with COTA. AI safety and research company Anthropic is partnering with international biotech company Genmab to build custom Claude-powered agentic AI capabilities aligned with Genmab's research and development processes. Anthropic's AI assistant and large language model (LLM), Claude, will be used by Genmab's team for data processing, analysis and document generation, with human oversight and guardrails, to assist with operational activities and improve consistency within clinical programs. "Clinical development is critical, heavily regulated and directly tied to patient outcomes. This is why we're partnering with an innovative and patient-focused biotech company like Genmab as they apply AI to support their clinical development process," Kate Jensen, head of Americas at Anthropic, said in a statement. "We're working closely with Genmab to deploy Claude and build custom agentic solutions with the intention to help their team focus on the hard problems that require human expertise and get therapies to patients faster." Hippocratic AI, a generative AI company focused on administrative healthcare tasks, is partnering with global consulting firm Boston Consulting Group (BCG) to help the biopharma and medtech industries implement generative AI healthcare agents. Hippocratic AI's generative AI focuses on nondiagnostic healthcare tasks such as medication onboarding, monthly reconciliation, answering hospital and payer policy questions, and providing EHR assistance. The companies said the partnership will combine Hippocratic AI's and BCG's expertise to help life sciences organizations generate value from AI technology and move from experimentation to enterprise-scale impact. "Our collaboration with BCG is built on a shared commitment to improving patient outcomes," Munjal Shah, founder and CEO of Hippocratic AI, said in a statement. "By combining BCG's deep strategic and operational expertise with our safety-focused generative AI health care agents, we can accelerate innovation across biopharma and medtech, bringing scalable, empathetic, and clinically aligned support to patients, providers, and researchers around the world." Real-world clinical data analytics company Verana Health has merged with oncology-focused data company COTA. Verana Health combines clinical expertise with real-world data to help providers access real-world evidence and obtain clinical insights. COTA focuses specifically on cancer care data, offering oncology research and development, regulatory, commercial, and health economics and outcomes research (HEOR) teams with patient data to help discover new treatment protocols for cancer care. Verana said in a statement that the merger adds high-fidelity oncology datasets and analytics to its offerings and strengthens its relationships within the biopharma industry, as the combined company will serve 17 of the top 20 global biopharma companies. "This is a unique opportunity to better serve organizations with advanced curation technology and real-world insights across multiple specialty therapeutic areas. This combination raises the bar for clinical expertise, data quality, validation, and transparency, so our partners can generate evidence with the utmost confidence," Sujay Jadhav, CEO of Verana Health, said in a statement.
CTG partners with Hippocratic AI to bring safe, patient-focused agentic AI to U.S. Healthcare organizations. CTG, a Cegeka company delivering IT and business solutions that enhance clients' digital agility, announced today a strategic partnership with Hippocratic AI, the global leader and pioneer of safety-focused, patient-facing clinical generative AI agents for healthcare. CTG is proud to offer managed AI and transformational consulting services to expand the implementation of Hippocratic AI's solution in the U.S. market. CTG brings decades of experience optimizing EHR, ERP, and clinical workflows, making it uniquely positioned to help healthcare organizations realize the full potential of Hippocratic AI through its managed services, performance improvement, and digital transformation expertise. Hippocratic AI was founded with a mission to achieve healthcare abundance by improving outcomes and reducing strain on the healthcare system through clinically safe AI agents. True to its namesake, Do No Harm, Hippocratic AI places patient safety above all else. Its patented Polaris Safety Constellation Architecture has been clinically tested and validated through a network of more than 7,000 licensed U.S. clinicians and has completed over 500,000 test calls, setting a new benchmark for safe, scalable, and clinically sound AI. The company's AI agents have surpassed 115 million real-world patient interactions. Serving providers, payers, and life science organizations, Hippocratic AI's generative AI agents power more than 1,000 use cases showcasing quality improvement, care management, readmission reduction, health equity, compliance, and preventive care, to name a few. Hippocratic AI is pioneering a new standard for healthcare AI agents, powered by rigorously clinically tested large language models (LLMs) to engage patients and providers. Through this partnership, CTG and Hippocratic AI will empower healthcare organizations to: * Scale patient outreach and increase care team capacity * Support at-risk patients with timely follow-up and care coordination * Improve care team efficiency by independently managing routine clinical conversations and sending urgent (red) escalations in real time to nurses * Boost clinical readiness for upcoming appointments, procedures, and surgeries with automated reminders * Execute health campaigns for preventative screenings, immunizations, and public health alerts * Close care gaps with multilingual AI agents that deliver a personalized, patient-centric experience "Healthcare organizations are under extraordinary pressure to do more with less, expanding access, closing care gaps, and improving patient engagement," said Dan Stoke, Vice President of Healthcare at CTG. "Through this partnership, we're equipping our clients with innovative AI-driven solutions that extend the reach of clinical teams, enhance patient experience, and expand access to care across the care continuum, all while maintaining an unwavering commitment to patient safety." "Our partnership with CTG supports Hippocratic AI's mission to bring safe, clinically validated generative AI into healthcare at scale," said Bill Hudson, Chief Information Officer at Hippocratic AI. "CTG's leadership in healthcare IT and digital transformation makes them the ideal implementation partner as we work together to improve patient access, reduce administrative burden, and ensure patients receive timely, high-quality touchpoints that improve patient lives." CTG and Hippocratic AI are jointly developing an AI agent that transforms routine patient support into meaningful clinical engagement. This next-generation agent is designed to assist patients with accessing their records through the patient's health portal. This innovative solution reimagines routine support calls, such as password resets or help locating test results, as opportunities for meaningful clinical engagement. Rather than routing patients through multiple teams, the AI agent is trained to recognize and act on potential clinical needs in real-time. For example, if a patient calls to retrieve test results, the agent can automatically help schedule follow-up appointments or close care gaps based on those results. By embedding clinical intelligence into everyday support experiences, CTG and Hippocratic AI are helping healthcare organizations turn ordinary support moments into compassionate, personalized care connections. CTG, a Cegeka company, delivers IT and business solutions that enhance clients' digital agility, empowering them to seize new opportunities and overcome challenges. Our expertise, grounded in more than 55 years' experience, drives data-driven decisions, boosts business performance, enhances client experiences, fosters continuous innovation, and elevates cyber resilience. CTG combines local Americas market knowledge with the global expertise of over 10,000 Cegeka Group team members in more than 17 countries to provide innovative, tailored solutions. Together, we operate across the Americas, Europe, and India, working with over 3,000 clients in high-growth industries. CTG is a Great Place to Work Certifiedtm company. Visit www.ctg.com. About Hippocratic AI Hippocratic AI has developed the safest generative AI Agents for healthcare. The company believes that generative AI has the ability to bring healthcare abundance to every person in the world. The company focuses on building non-diagnostic patient-facing clinical AI agents and does not allow its agents to be used to prescribe or diagnose. Hippocratic AI has received a total of $404 million in funding and is backed by leading investors, including Andreessen Horowitz, General Catalyst, Kleiner Perkins, Avenir, NVIDIA's NVentures, Premji Invest, SV Angel, Google's CapitalG, and numerous health systems. Learn more at https://hippocraticai.com/. | these press releases may also interest you | at 08:30 | lendingpoint announces strategic capital raise to accelerate growth in 2026 and beyond | | / | lendingpoint, the award winning, AI-driven fintech facilitating consumer credit origination and loan servicing, today announced a new round of capital financing that positions the company for significant expansion and market acceleration in 2026... | | 14 nov 2025 | avicanna reports Q3 2025 | | / | avicanna inc. ("avicanna" or "company") a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q3 2025. Management... | | 14 nov 2025 | COSCIENS biopharma inc. announces leadership change | | / | COSCIENS biopharma inc. (FINRA: CSCIF) ("COSCIENS" or the "company"), a life science company focused on natural ingredients and pharmaceutical solutions, announced today that peter H. Puccetti, CFA, chairman of the company's board of directors (the... | | 14 nov 2025 | university of phoenix college of doctoral studies researchers present on harnessing generative AI tools for student engagement at 2025 AECT international convention | | / | researchers from the university of phoenix college of doctoral studies center for educational and instructional technology research (CEITR) presented "transforming higher education: harnessing generative AI for student engagement" at the 2025... | | 14 nov 2025 | repare therapeutics enters into definitive agreement to be acquired by xenotherapeutics, inc. | | / | repare therapeutics inc. ("repare" or the "company"), a clinical-stage precision oncology company, today announced that it has entered into a definitive arrangement agreement (the "arrangement agreement") with xenotherapeutics, inc. and xeno... | | 14 nov 2025 | elastic named a leader in 2025 IDC marketscape for worldwide observability platforms | | / | elastic, the search AI company, has been named a leader in the IDC marketscape: worldwide observability platforms 2025 vendor assessment (doc #US53004325, november 2025). According to the IDC marketscape report, "elastic's overarching strength is... | | / | more news about science and technology... News published on 10 november 2025 at 10:55 and distributed by: